Results 101 to 110 of about 334,888 (299)

Effect of a Clinical Evidence Technology on Patient Skin Disease Outcomes in Primary Care: A Cluster-Randomized Controlled Trial [PDF]

, 2018
Objective: Providers’ use of clinical evidence technologies (CETs) improves their diagnosis and treatment decisions. Despite these benefits, few studies have evaluated the impact of CETs on patient outcomes. Investigators evaluated the effect of one CET,
Burke, Marianne, Littenberg, Benjamin, MD   +1 more
core   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Improved Designs for Cluster Randomized Trials [PDF]

Annual Review of Public Health, 2016
Studies in which clusters of individuals are randomized to conditions are increasingly common in public health research. However, the designs utilized for such studies are often suboptimal and inefficient. We review strategies to improve the design of cluster randomized trials. We discuss both older but effective design concepts that are underutilized,
openaire   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

A school-based intervention improved dietary intake outcomes and reduced waist circumference in adolescents: a cluster randomized controlled trial

Nutrition Journal, 2017
Background In Ecuador, adolescents’ food intake does not comply with guidelines for a healthy diet. Together with abdominal obesity adolescent’s inadequate diets are risk factors for non-communicable diseases.
Angélica Ochoa-Avilés, Roosmarijn Verstraeten, Lieven Huybregts, Susana Andrade, John Van Camp, Silvana Donoso, Patricia Liliana Ramírez, Carl Lachat, Lea Maes, Patrick Kolsteren   +9 more
doaj   +1 more source

Cluster randomized test-negative design (CR-TND) trials: a novel and efficient method to assess the efficacy of community level dengue interventions

, 2018
Cluster randomized trials are the gold standard for assessing efficacy of community-level interventions, such as vector control strategies against dengue.
Anders, KL, Cutcher, Z, Donnelly, CA, Ferguson, NM, Indriani, C, Jewell, NP, Kleinschmidt, I, O'Neill, SL, Ryan, PA, Simmons, CP   +9 more
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Implementation strategies to integrate HIV and hypertension care in Kampala and Wakiso districts, Uganda: study protocol for a stepped wedge cluster randomized trial (PULESA-Uganda)

BMC Health Services Research
Background Hypertension (HTN) is the leading cause of cardiovascular morbidity and mortality among people living with HIV (PLWH) in Africa, yet integration of hypertension treatment in HIV clinics is sub-optimal.
Chris T. Longenecker, John Baptist Kiggundu, Florence Ayebare, Martin Muddu, James Kayima, Gerald Mutungi, Isaac Ssinabulya, Jeremy I. Schwartz, Donna Spiegelman, Guangyu Tong, Rachel Nugent, Angela Aifah, Faith Kagoya, Drew B. Cameron, Brian Hutchinson, Moses R. Kamya, Anne R. Katahoire, Fred C. Semitala   +17 more
doaj   +1 more source

Dual-mobIlity verSus conventional Total hip arthroplasty In femoral Neck fractures, a registry-nested, open-label, Cluster-randomized crossover Trial (DISTINCT): statistical analysis plan

Bone & Joint Open
Aims: A statistical analysis plan for analysis of DISTINCT (Dual-mobIlity verSus conventional Total hip arthroplasty In femoral Neck fractures, a registry-nested, open-label, Cluster-randomized crossover Trial) is outlined to aid transparency in ...
The DISTINCT Study Group
doaj   +1 more source

Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

, 2013
Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS).
Friede, Tim, Nicholas, Richard, Röver, Christian, Schneider, Simon, Steinvorth, Simon M., Straube, Sebastian   +5 more
core   +1 more source